JMIR dermatology最新文献

{"title":"Assessment of Quality and Utility of Patient-Taken Smartphone Photographs of Atopic Dermatitis: Clinical Survey Study.","authors":"Zarqa Ali, Kenneth Thomsen, Christian Vestergaard, Simon Francis Thomsen","doi":"10.2196/72916","DOIUrl":"10.2196/72916","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) has a relapsing and remitting nature, and scheduled clinic visits only provide a snapshot of the skin condition at the moment.</p><p><strong>Objective: </strong>This study aimed to investigate the quality of patient-taken smartphone photographs of AD skin lesions and characterize patients using smartphone photographs as a tool to assist the physician to show disease activity in between consultations.</p><p><strong>Methods: </strong>Patients from 2 university outpatient clinics specialized in AD were surveyed. A questionnaire regarding digital readiness was completed, and a previously taken skin lesion photograph on the patients' own smartphone was evaluated.</p><p><strong>Results: </strong>Between February 2024 and September 2024, a total of 100 questionnaires were completed, 60 (60%) by participants from the capital region of Denmark and 40 (40%) by participants from an urban area, including 62 (62%) men and 38 (38%) women. The mean age of the recruited patients was 33.9 (SD 19.9) years. A total of 78% (78/100) of the patients used a desktop computer, laptop, or tablet often or always, and 86% (86/100) corresponded with the health care system using technology (eg, via email to the general practitioner or contact with hospitals via apps). More than 50% (52/100, 52%) strongly agreed or agreed with the statement that they would prefer a remote online visit with, for example, upload of skin lesion photographs over a routine in-person office visit. Almost 3 out of 4 patients had a photograph of their AD skin lesion on their smartphone, most (38/71, 54%) with the sole intention of presenting it to a physician. The photographs were of good quality in 85% (60/71) of the cases, and most (61/71, 86%) of the smartphone photographs were assessed to be useful for diagnostic and clinical evaluation. Receiving topical monotherapy was significantly associated with increased risk of having taken a skin lesion smartphone photograph (P=.006).</p><p><strong>Conclusions: </strong>Patients with AD followed up on in an outpatient clinic often took good-quality photographs of their skin lesions before consultations with the intention of presenting them to the physician.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"9 ","pages":"e72916"},"PeriodicalIF":0.0,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12844854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146069233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Satisfaction, Side Effects, and Other Reactions Reported by Adult Men Prescribed Compounded Topical Finasteride via a National Telehealth Platform: Retrospective Analysis of Real-World Data.","authors":"Jessica Yu, Sachie Mochida, Michele Emery, Patrick Carroll, Justin Ko, Arash Mostaghimi","doi":"10.2196/84676","DOIUrl":"10.2196/84676","url":null,"abstract":"<p><strong>Background: </strong>Topical minoxidil and oral finasteride are approved by the US Food and Drug Administration (FDA) for the treatment of male androgenetic alopecia (AGA). However, concerns about adverse events related to the use of oral finasteride have led to some apprehension about the treatment. Topical finasteride, though not FDA-approved, has demonstrated efficacy and safety in a limited number of clinical trials and may be a promising alternative, such that compounding pharmacies and telehealth companies in the United States now offer access to topical finasteride for patients with AGA.</p><p><strong>Objective: </strong>This real-world, retrospective study is, to our knowledge, the largest study to date aimed to evaluate patient satisfaction and tolerability associated with the novel combinations of topical finasteride and topical minoxidil for the treatment of male AGA.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patient data collected during routine clinical follow-up via Hims & Hers, a direct-to-consumer health and wellness platform, between April 1, 2021 and April 30, 2025 to assess the frequency of side effects and other possible medication reactions associated with the use of compounded topical finasteride and minoxidil. Data were gathered from two sources: (1) a follow-up check-in sent to patients approximately 130 days following the initiation of treatment; (2) unprompted communications sent via in-app or web-based messaging from patients to their care team. Data about patient satisfaction with treatment, the frequency of any side effect, frequency of specific side effects, need for a higher level of care, and treatment discontinuation due to a side effect were extracted from the data sources.</p><p><strong>Results: </strong>A total of 638,629 male patients with AGA received a prescription for a compounded topical finasteride and minoxidil product between April 1, 2021 and April 30, 2025. Of 151,352 (23.7%) patients who completed a follow-up check-in, 121,615 (80.4%) reported being satisfied with treatment and 4034 (2.7%) reported experiencing a side effect. Of all the 638,629 patients, 230 (0.04%) sent their care team a message (outside of check-ins) indicating a side effect or other possible medication reactions. No patient reported seeking a higher level of care or discontinued treatment due to such an occurrence.</p><p><strong>Conclusions: </strong>Patients prescribed novel formulations of compounded topical finasteride and minoxidil for the treatment of AGA via a national telehealth platform reported satisfaction with the treatment and tolerated it well. The limitations of the study include the use of retrospective data and the lack of a control group, both of which preclude causal inference. Future research should include randomized controlled trials to assess the efficacy, safety, and tolerability of topical finasteride.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"9 ","pages":"e84676"},"PeriodicalIF":0.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12826577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Skin Cancer With Clinical Depression and Poor Mental Health Days: Cross-Sectional Analysis.","authors":"Riona Ray, Mytien Nguyen","doi":"10.2196/80710","DOIUrl":"10.2196/80710","url":null,"abstract":"<p><strong>Background: </strong>Mental health is becoming increasingly recognized as an important part of overall health, especially for patients with cancer. However, the relationship between nonmelanoma skin cancer and mental health has not been widely studied.</p><p><strong>Objective: </strong>The aim of this study was to examine the association between nonmelanoma skin cancer diagnosis and 2 key mental health outcomes (ie, clinical depression and the number of poor mental health days).</p><p><strong>Methods: </strong>This study used the 2023 Behavioral Risk Factor Surveillance System, a nationally representative survey of adults in the United States, which included 312,317 participants. Nonmelanoma skin cancer diagnosis, depression, and self-reported mental health days were analyzed. Logistic regression was used to evaluate the association between nonmelanoma skin cancer and depression, whereas Poisson regression was used to model the number of poor mental health days, adjusting for age, sex, race and ethnicity, education, BMI, income, and major comorbid conditions (other cancers, heart disease, lung disease, and kidney disease).</p><p><strong>Results: </strong>Individuals with nonmelanoma skin cancer (5086/26,552, 19.15%) reported a lower overall rate of depression compared to those without nonmelanoma skin cancer (61,438/285,765, 21.50%; P<.001) but reported more poor mental health days on average (4.54, SD 8.37 d vs 3.20, SD 7.37 d; P<.001). After adjustment, nonmelanoma skin cancer diagnosis was not significantly associated with depression (adjusted odds ratio 1.01, 95% CI 0.98-1.05) and was associated with a slightly lower number of poor mental health days (adjusted rate ratio 0.94, 95% CI 0.91-0.97).</p><p><strong>Conclusions: </strong>Adults with nonmelanoma skin cancer experienced a meaningful mental health burden, and unadjusted analyses suggested greater day-to-day distress than among adults without nonmelanoma skin cancer. However, these differences were reduced and no longer significant for depression after adjusting for sociodemographic factors and comorbid chronic illnesses. These findings support the need for mental health screenings and support services in dermatologic and oncologic care.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"9 ","pages":"e80710"},"PeriodicalIF":0.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12826630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146031924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Perceptions of Climate Change Impacts on Atopic Dermatitis: Cross-Sectional Survey Study.","authors":"Gunnar Mattson, Sarah Coates, Amanda R Twigg","doi":"10.2196/80679","DOIUrl":"10.2196/80679","url":null,"abstract":"<p><strong>Unlabelled: </strong>This cross-sectional survey study (63.5% response rate) characterized how patients with atopic dermatitis (AD) perceive and experience the effects of climate change on their AD. Most participants reported that environmental factors such as heat and air pollution worsened their AD and expressed a desire for climate-health education, yet few had discussed these concerns with their dermatologist. These findings reveal a gap in patient-centered dermatologic care and support the development of tools to integrate environmental health into atopic dermatitis management.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"9 ","pages":"e80679"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12820409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146013470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging AI Large Language Models for Writing Clinical Trial Proposals in Dermatology: Instrument Validation Study.","authors":"Megan Hauptman, Daniel Copley, Kelly Young, Tran Do, Joseph S Durgin, Albert Yang, Jungsoo Chang, Allison Billi, Mio Nakamura, Trilokraj Tejasvi","doi":"10.2196/76674","DOIUrl":"10.2196/76674","url":null,"abstract":"<p><strong>Background: </strong>Large language models (LLMs) are becoming increasingly popular in clinical trial design but have been underused in research proposal development.</p><p><strong>Objective: </strong>This study compared the performance of commonly used open access LLMs versus human proposal composition and review.</p><p><strong>Methods: </strong>A total of 10 LLMs were prompted to write a research proposal. Six physicians and each of the LLMs assessed 11 blinded proposals for capabilities and limitations in accuracy and comprehensiveness.</p><p><strong>Results: </strong>ChatGPT-o1 and Llama 3.1 were rated the most and least accurate, respectively, by human scorers. LLM scorers rated ChatGPT-o1 and DeepSeek R1 as the most accurate. ChatGPT-o1 and Llama 3.1 were rated as the most and least comprehensive, respectively, by human and LLM scorers. LLMs performed poorly on scoring proposals and, on average, rated proposals 1.9 points higher than humans for both accuracy and comprehensiveness.</p><p><strong>Conclusions: </strong>Paid versions of ChatGPT remain the highest-quality and most versatile option of the available LLMs. These tools cannot replace expert input but serve as powerful assistants, streamlining the development process and enhancing productivity.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"9 ","pages":"e76674"},"PeriodicalIF":0.0,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Over- and Underfunded Diseases by Comparing National Institutes of Health Funding for Skin Disease Research With US Skin Disease Burden According to 2021 Global Burden of Disease Data: Cross-Sectional Analysis.","authors":"Aileen Park, Emily Woolhiser, Hannah Riva, Leo Wan, Haaris Kadri, Elizabeth Lamberty, Parker Juels, Sandra Jaroonwanichkul, Madison Reed, Catherine Hegedus, Dana Chen, Danielle Duffle, Jessica Kirk, Sydney Christensen, Emma Shelby, Robert Dellavalle","doi":"10.2196/71468","DOIUrl":"10.2196/71468","url":null,"abstract":"<p><strong>Background: </strong>Understanding the burden of various skin diseases can help guide funding allocation for skin disease research. A 2015 cross-sectional study found a partial correlation between US skin disease burden according to the 2010 Global Burden of Disease (GBD) study and National Institutes of Health (NIH) funding in 2012-2013.</p><p><strong>Objective: </strong>This study aims to identify trends, correlations, and disparities in US skin disease burden and NIH research funding allocation using the latest data from the GBD 2021 and NIH funding data from the fiscal years 2021-2022.</p><p><strong>Methods: </strong>A cross-sectional analysis was conducted to compare the disability-adjusted life years for 15 skin conditions from the GBD 2021 with NIH funding for these conditions in 2021-2022. Data were sourced from the GBD Results tool and the NIH RePORTER database.</p><p><strong>Results: </strong>NIH funding for skin disease research and US skin disease burden according to the GBD 2021 were partially correlated, with several outliers. Malignant skin melanoma and pruritus were relatively overfunded, while psoriasis and urticaria were relatively underfunded.</p><p><strong>Conclusions: </strong>Disease burden is just one of the many important factors that must be considered when allocating resources, including funding to encourage research efforts to improve patient outcomes and positively impact public health.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"9 ","pages":"e71468"},"PeriodicalIF":0.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12773694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy, Implementation Barriers, and Equity Implications of Teledermatology in Rural Skin Cancer: Scoping Review.","authors":"Andres D Parga, Dorothy S Peng, Toan N Vu, Selene M Kizy, Aisha Khan","doi":"10.2196/77443","DOIUrl":"10.2196/77443","url":null,"abstract":"<p><strong>Background: </strong>Skin cancer is the most commonly diagnosed malignancy in the United States, with rural populations facing disproportionate delays in diagnosis due to geographic isolation, workforce shortages, and limited access to dermatologic care. These delays contribute to higher rates of late-stage diagnosis and poorer outcomes. Teledermatology has emerged as a promising solution to expand access to dermatologic evaluation and treatment in underserved settings.</p><p><strong>Objective: </strong>The review aims to evaluate the diagnostic performance, implementation challenges, and equity considerations of teledermatology in the context of rural skin cancer care, and to assess its potential to improve clinical outcomes in underserved populations.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar to identify studies published between January 2015 and March 2025. Search terms included \"teledermatology,\" \"skin cancer,\" \"rural health services,\" \"telemedicine,\" \"diagnostic accuracy,\" and \"health disparities.\" Studies evaluating diagnostic metrics, time to diagnosis, patient satisfaction, and implementation barriers were included.</p><p><strong>Results: </strong>Nine key studies spanning various countries and health care settings were included. Diagnostic sensitivity ranged from 41.9% to 100%, and specificity from 46% to 90%, depending on modality and lesion type. Teledermatology consistently reduced time to diagnosis, in some cases by over 75%, and was associated with high patient satisfaction due to increased convenience and reduced travel. Key barriers included technological limitations, inconsistent imaging protocols, and reimbursement variability. Successful implementation was facilitated by standardized workflows, dermoscopy integration, and centralized platforms.</p><p><strong>Conclusions: </strong>Teledermatology is a viable and effective approach to addressing disparities in rural skin cancer care. It offers diagnostic accuracy comparable to face-to-face evaluations while reducing wait times and improving patient satisfaction. Overcoming technological and systemic barriers is critical to ensuring equitable, long-term integration of teledermatology in rural health systems.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"8 ","pages":"e77443"},"PeriodicalIF":0.0,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12747661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145859477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review.","authors":"Finn Abeck, Inga Hansen-Abeck, Julian Kött, Edward Garrahy, Stefan W Schneider, Johannes von Büren","doi":"10.2196/72704","DOIUrl":"10.2196/72704","url":null,"abstract":"<p><strong>Unlabelled: </strong>This narrative review examines the advantages and disadvantages of direct-to-consumer teledermatology for the treatment of male androgenetic alopecia, finding that this treatment modality improves access to care, ensures high adherence rates, and enhances patient satisfaction, while raising concerns about increased drug costs.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"8 ","pages":"e72704"},"PeriodicalIF":0.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12716827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145795659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing the VISIA Camera for Analyzing 5-Fluorouracil Treatment Efficacy for Actinic Keratosis.","authors":"Emily Woolhiser, Leena Jamal, Jessica Kirk, Bertha Baum, Robert Dellavalle","doi":"10.2196/66553","DOIUrl":"10.2196/66553","url":null,"abstract":"<p><strong>Unlabelled: </strong>The VISIA camera is a device that captures images of the skin, offering a detailed look at skin health by detecting changes that are often missed during physical exams and by the naked eye. It can help identify changes in UV damage, pigmentation, texture, fine lines, and redness. In dermatology, it has become a useful tool to build targeted treatment plans and follow patient progress over time. We present a case of a male patient diagnosed with diffuse scalp actinic keratoses who was treated with topical 5-fluorouracil (5-FU). VISIA images were taken before treatment, at one week, and again three months following therapy. The images were reviewed for changes in UV spots, texture, and other generalized spots. Results revealed a decrease in UV spots, a temporary improvement in texture followed by a later rise, and no significant change in generalized spots. This case highlights the value of VISIA imaging as an objective method for assessing treatment response and evaluating the effectiveness of 5-FU in the management of actinic keratoses.</p>","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"8 ","pages":"e66553"},"PeriodicalIF":0.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12716630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145795654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3D Total Body Photography as a Promising Innovation for Early Skin Cancer Detection: Scoping Review.","authors":"Fran Baete, Alyssa Laura Jakers, Emilie Delanoye, Nele Vande Velde, Griet Voet","doi":"10.2196/68510","DOIUrl":"10.2196/68510","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Skin cancer (SC) is a global health concern because of its high and still increasing incidence and associated health care cost. Belgium is no exception as 1 in 5 people are diagnosed with SC before the age of 75 years. The VECTRA WB360, a 3D total body photography system, allows clinicians to objectively compare the totality of the skin on a macroscopic level on further appointments. The integrated lesion visualization software allows automated detection, counts, and assessment of skin lesions. Detailed comparison of individual lesions is possible through the attached digital dermatoscope.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study aims to review available literature on the use of the VECTRA in research and clinical settings and to summarize the clinical utility, advantages, and limitations reported for this system.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;An electronic literature search was conducted on PubMed from December 2023 to March 2024 using a combination of the following search terms: 3D imaging, VECTRA WB360, melanoma, nonmelanoma skin cancer, their synonyms, and associated entry terms. Publications that used a device other than the VECTRA WB360 were excluded, as were papers reporting on new technology without further research or without added cases. After a thorough screening of the papers and removal of duplicates, 11 papers remained.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Our literature search yielded 11 relevant papers, which included 2 case studies, 6 prospective studies, and 3 retrospective studies. According to multiple studies, the VECTRA WB360 images were of a high enough quality to allow on-screen diagnosis of some melanoma and nonmelanoma skin cancers by dermatologists. Sensitivity compared to face-to-face examination for melanoma is unknown. The integrated lesion visualization software is capable of detecting and counting naevi and distinguishing melanoma from other skin lesions with high accuracy, with convolutional neural network integration further enhancing its sensitivity and specificity. However, it is important to note that no comparison to the usual standard of care was made. Also, dermatologists achieved greater specificity and thus remained superior to machine and artificial intelligence (AI).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Although the VECTRA 3D TBP holds substantial promise for the early detection and monitoring of SC, its application cannot yet replace the expertise of trained clinicians. Although the lesion visualizer and dermoscopy explainable intelligence (DEXI) score offer potential enhancements, they also pose risks, including a significant increase in unnecessary excisions due to lower specificity. Expert overview is still recommended and superior, since there is not enough evidence yet that 3D TBP or AI is reliable on its own or beneficial as a support tool. Given the small samples and lack of blinded trials, further studies are needed to explore and improve the diagnostic capacitie","PeriodicalId":73553,"journal":{"name":"JMIR dermatology","volume":"8 ","pages":"e68510"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12710984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}